Tarek A Bismar1,2,3,4,5, Samar Hegazy6, Zhaoyong Feng7, Darryl Yu8, Bryan Donnelly9,10, Nallasivam Palanisamy11, Bruce J Trock7. 1. Department of Pathology and Laboratory Medicine, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada. tabismar@ucalgary.ca. 2. Departments of Oncology, Biochemistry and Molecular Biology, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada. tabismar@ucalgary.ca. 3. Arnie Charbonneau Cancer Institute, Tom Baker Cancer Center, Calgary, AB, Canada. tabismar@ucalgary.ca. 4. Prostate Cancer Center, Calgary, AB, Canada. tabismar@ucalgary.ca. 5. Rokyview General Hospital, Calgary Laboratory Services, 7007, 14th Street SW, Calgary, AB, T2V 1P9, Canada. tabismar@ucalgary.ca. 6. Department of Pathology and Laboratory Medicine, University of Calgary-Cumming School of Medicine, Calgary, AB, Canada. 7. Brady Urological Institute, John Hopkins School of Medicine, Baltimore, MD, USA. 8. Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. 9. Department of Urology, University of Calgary, Calgary, AB, Canada. 10. Prostate Cancer Center, Calgary, AB, Canada. 11. Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA.
Abstract
OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most common genetic aberration in men with prostate cancer managed non-surgically by androgen deprivation therapy (ADT). MATERIALS AND METHODS: 463 tumor samples were assessed by double immunohistochemistry stains for ERG and PTEN and data correlated with clinical pathological features including, Gleason score, patients' outcome and ADT. RESULTS: ERG expression and PTEN protein loss were present in 28.2% and 38% of total patients respectively. There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p < 0.001). Both ERG and PTEN showed significant association with lethal disease in all patients and those treated with prior ADT representing castrate-resistant disease. However, only PTEN remained significant in multivariable proportional hazards regression analysis, when including Gleason score and patients' age. Depending on patient's subgroup, intact positive PTEN intensity showed better cancer-specific survival with HR ranging from 0.25 to 0.4 compared to tumors with loss of PTEN expression. Assessing combined marker status, patients with decreased PTEN intensity without ERG positivity showed the worst clinical outcome compared to those with no PTEN loss and no ERG expression, where they had best clinical outcome. Patients with ERG expression with or without PTEN loss showed intermediate risk in relation to lethal disease. CONCLUSION: This study confirms a significant prognostic role for assessing ERG and PTEN in men with prostate cancer. It supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups.
OBJECTIVES: To assess the prognostic value of ERG and PTEN protein expression as two of the most common genetic aberration in men with prostate cancer managed non-surgically by androgen deprivation therapy (ADT). MATERIALS AND METHODS: 463 tumor samples were assessed by double immunohistochemistry stains for ERG and PTEN and data correlated with clinical pathological features including, Gleason score, patients' outcome and ADT. RESULTS:ERG expression and PTEN protein loss were present in 28.2% and 38% of total patients respectively. There was a significant interplay between ERG and PTEN expression with 21.8% PTEN negative tumors being ERG positive (p < 0.001). Both ERG and PTEN showed significant association with lethal disease in all patients and those treated with prior ADT representing castrate-resistant disease. However, only PTEN remained significant in multivariable proportional hazards regression analysis, when including Gleason score and patients' age. Depending on patient's subgroup, intact positive PTEN intensity showed better cancer-specific survival with HR ranging from 0.25 to 0.4 compared to tumors with loss of PTEN expression. Assessing combined marker status, patients with decreased PTEN intensity without ERG positivity showed the worst clinical outcome compared to those with no PTEN loss and no ERG expression, where they had best clinical outcome. Patients with ERG expression with or without PTEN loss showed intermediate risk in relation to lethal disease. CONCLUSION: This study confirms a significant prognostic role for assessing ERG and PTEN in men with prostate cancer. It supports a role for utilizing combined ERG/PTEN status clinically and prospectively for stratifying PCa patients into different prognostic groups.
Authors: Tarek A Bismar; Maisa Yoshimoto; Robin T Vollmer; Qiuli Duan; Matthew Firszt; Jacques Corcos; Jeremy A Squire Journal: BJU Int Date: 2011-02 Impact factor: 5.588
Authors: A Marije Hoogland; Guido Jenster; Wytske M van Weerden; Jan Trapman; Theo van der Kwast; Monique J Roobol; Fritz H Schröder; Mark F Wildhagen; Geert Jlh van Leenders Journal: Mod Pathol Date: 2011-11-11 Impact factor: 7.842
Authors: Alan Dal Pra; Emilie Lalonde; Jenna Sykes; Fiona Warde; Adrian Ishkanian; Alice Meng; Chad Maloff; John Srigley; Anthony M Joshua; Gyorgy Petrovics; Theodorus van der Kwast; Andrew Evans; Michael Milosevic; Fred Saad; Colin Collins; Jeremy Squire; Wan Lam; Tarek A Bismar; Paul C Boutros; Robert G Bristow Journal: Clin Cancer Res Date: 2013-08-05 Impact factor: 12.531
Authors: Maisa Yoshimoto; Anthony M Joshua; Isabela W Cunha; Renata A Coudry; Francisco P Fonseca; Olga Ludkovski; Maria Zielenska; Fernando A Soares; Jeremy A Squire Journal: Mod Pathol Date: 2008-05-23 Impact factor: 7.842
Authors: Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami Journal: JAMA Date: 2004-06-09 Impact factor: 56.272
Authors: Kuo-Cheng Huang; Mohammed Alshalalfa; Samar A Hegazy; Michael Dolph; Bryan Donnelly; Tarek A Bismar Journal: Cancer Biol Ther Date: 2014-06-27 Impact factor: 4.742
Authors: A H M Reid; G Attard; L Ambroisine; G Fisher; G Kovacs; D Brewer; J Clark; P Flohr; S Edwards; D M Berney; C S Foster; A Fletcher; W L Gerald; H Møller; V E Reuter; P T Scardino; J Cuzick; J S de Bono; C S Cooper Journal: Br J Cancer Date: 2010-01-26 Impact factor: 7.640
Authors: Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar Journal: J Cancer Res Clin Oncol Date: 2020-04-30 Impact factor: 4.553
Authors: Andrea Bakker; Jonathan C Slack; Nalla Palanisamy; Shannon Carskadon; Sunita Ghosh; Ibrahim Khalifeh; Tarek A Bismar Journal: J Cancer Res Clin Oncol Date: 2022-08-18 Impact factor: 4.322
Authors: Simon R Walker; Ramy Abdelsalam; Sunita Ghosh; Julie Livingstone; Nallasivam Palanisamy; Paul C Boutros; Steven M Yip; Susan P Lees-Miller; Tarek A Bismar Journal: Eur Urol Open Sci Date: 2021-06-12